{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:52:50Z","timestamp":1789944770681,"version":"4.0.1"},"reference-count":181,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/hrp.0000000000000030","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T13:05:52Z","timestamp":1394456752000},"page":"76-92","source":"Crossref","is-referenced-by-count":59,"title":["Psychopharmacological Interventions in Autism Spectrum Disorder"],"prefix":"10.1097","volume":"22","author":[{"given":"Laura C.","family":"Politte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20210129","first-page":"1","article-title":"2008 Prinicipal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disordersAutism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.","volume":"61","year":"2012","journal-title":"MMWR Surveill Summ"},{"issue":"65","key":"R3-3-20210129","first-page":"1","article-title":"Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012.","author":"Blumberg","year":"2013","journal-title":"Natl Health Stat Report"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaac.2012.06.017","article-title":"Caregiver burden as people with autism spectrum disorder and attention-deficithyperactivity disorder transition into adolescence and adulthood in the United Kingdom.","volume":"51","author":"Cadman","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1542\/peds.2011-2700","article-title":"Implications of childhood autism for parental employment and earnings.","volume":"129","author":"Cidav","year":"2012","journal-title":"Pediatrics"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/DBP.0b013e31823969de","article-title":"Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions.","volume":"33","author":"Peacock","year":"2012","journal-title":"J Dev Behav Pediatr"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1362361309103791","article-title":"The costs of services and employment outcomes achieved by adults with autism in the US.","volume":"13","author":"Cimera","year":"2009","journal-title":"Autism"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/070674371205700503","article-title":"Services for adults with an autism spectrum disorder.","volume":"57","author":"Shattuck","year":"2012","journal-title":"Can J Psychiatry"},{"key":"R9-3-20210129","first-page":"CD009260","article-title":"Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD).","volume":"10","author":"Reichow","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10803-010-0996-9","article-title":"The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population.","volume":"40","author":"Joshi","year":"2010","journal-title":"J Autism Dev Disord"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/aur.133","article-title":"Association between depression and anxiety in high-functioning children with autism spectrum disorders and maternal mood symptoms.","volume":"3","author":"Mazefsky","year":"2010","journal-title":"Autism Res"},{"key":"R13-3-20210129","first-page":"193","article-title":"Overrepresentation of mood and anxiety disorders in adults with autism and their first-degree relatives: what does it mean Autism R","volume":"1","author":"Mazefsky","year":"2008","journal-title":"es"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.rasd.2011.06.015","article-title":"Depression and anxiety symptoms in children and adolescents with autism spectrum disorders without intellectual disability.","volume":"6","author":"Strang","year":"2012","journal-title":"Res Autism Spectr Disord"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/0883073807309783","article-title":"Melatonin for insomnia in children with autism spectrum disorders.","volume":"23","author":"Andersen","year":"2008","journal-title":"J Child Neurol"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2869.2012.01021.x","article-title":"Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial.","volume":"21","author":"Cortesi","year":"2012","journal-title":"J Sleep Res"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2214.2006.00616.x","article-title":"Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems.","volume":"32","author":"Garstang","year":"2006","journal-title":"Child Care Health Dev"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10803-006-0116-z","article-title":"An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism.","volume":"36","author":"Giannotti","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.smrv.2011.02.001","article-title":"Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion.","volume":"15","author":"Guenole","year":"2011","journal-title":"Sleep Med Rev"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-079X.2007.00528.x","article-title":"A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities.","volume":"44","author":"Wasdell","year":"2008","journal-title":"J Pineal Res"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5664\/jcsm.27443","article-title":"The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.","volume":"5","author":"Wirojanan","year":"2009","journal-title":"J Clin Sleep Med"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10803-010-1036-5","article-title":"Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.","volume":"41","author":"Wright","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.biopsych.2006.09.021","article-title":"Early pharmacological treatment of autism: a rationale for developmental treatment.","volume":"61","author":"Bethea","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample.","volume":"47","author":"Simonoff","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.44.7.1309","article-title":"Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.","volume":"44","author":"Brasic","year":"1994","journal-title":"Neurology"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/cap.1997.7.109","article-title":"Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.","volume":"7","author":"Brodkin","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/00004583-199207000-00025","article-title":"Clomipramine in autism: preliminary evidence of efficacy.","volume":"31","author":"McDougle","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004583-199709000-00006","article-title":"Adverse effects of clomipramine.","volume":"36","author":"Brasic","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00004583-199604000-00021","article-title":"A pilot study of clomipramine in young autistic children.","volume":"35","author":"Sanchez","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.149.3.363","article-title":"Differential response of seven subjects with autistic disorder to clomipramine and desipramine.","volume":"149","author":"Gordon","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00004583-199105000-00029","article-title":"Fluoxetine in autism with depression.","volume":"30","author":"Ghaziuddin","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R34-3-20210129","first-page":"353","article-title":"Open study of fluoxetine in children with autism.","volume":"28","author":"Alcami Pertejo","year":"2000","journal-title":"Actas Espanolas de Psiquiatria"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S1461145701002280","article-title":"Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study.","volume":"4","author":"Buchsbaum","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"key":"R37-3-20210129","first-page":"507","article-title":"Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998; 40: 551-62. Comment: Bax M. A treatment that works.","volume":"40","author":"DeLong","year":"1998","journal-title":"Dev Med Child Neurol"},{"key":"R38-3-20210129","first-page":"333","article-title":"Sertraline response in adults with mental retardation and autistic disorder.","volume":"57","author":"Hellings","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"R39-3-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00004714-199802000-00010","article-title":"Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.","volume":"18","author":"McDougle","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R40-3-20210129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00004703-200304000-00005","article-title":"Use of citalopram in pervasive developmental disorders.","volume":"24","author":"Namerow","year":"2003","journal-title":"J Dev Behav Pediatr"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders.","volume":"44","author":"Owley","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0253-7176.70522","article-title":"An open-label trial of risperidone and fluoxetine in children with autistic disorder.","volume":"32","author":"Desousa","year":"2010","journal-title":"Indian J Psychol Med"},{"key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/cap.2006.16.187","article-title":"Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review.","volume":"16","author":"Henry","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":"Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.","volume":"7","author":"Steingard","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R45-3-20210129","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.","volume":"53","author":"McDougle","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1176\/appi.ajp.2011.10050764","article-title":"A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.","volume":"169","author":"Hollander","year":"2012","journal-title":"Am J Psychiatry"},{"key":"R47-3-20210129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1005551523657","article-title":"Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.","volume":"30","author":"McDougle","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R49-3-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R51-3-20210129","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/00004583-200211000-00021","article-title":"Genetics of childhood disorders: XLIV. Autism, part 3: psychopharmacology of autism.","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R52-3-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1345\/aph.1K427","article-title":"Buspirone for autistic disorder in a woman with an intellectual disability.","volume":"42","author":"Brahm","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R53-3-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4088\/JCP.v59n0203","article-title":"Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.","volume":"59","author":"Buitelaar","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R54-3-20210129","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archfami.6.4.368","article-title":"Treatment with buspirone in a patient with autism.","volume":"6","author":"McCormick","year":"1997","journal-title":"Arch Fam Med"},{"key":"R55-3-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00004714-198904000-00009","article-title":"Clinical effect of buspirone in autistic children.","volume":"9","author":"Realmuto","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pediatrneurol.2005.10.023","article-title":"Compulsive masturbation in infantile autism treated by mirtazapine.","volume":"34","author":"Albertini","year":"2006","journal-title":"Pediatr Neurol"},{"key":"R57-3-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/cap.2008.020","article-title":"Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder.","volume":"19","author":"Coskun","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R58-3-20210129","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/cap.2007.0014","article-title":"Mirtazapine treatment in a subject with autistic disorder and fetishism.","volume":"18","author":"Coskun","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R59-3-20210129","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00004583-200108000-00004","article-title":"Mirtazapine for excessive masturbation in an adolescent with autism.","volume":"40","author":"Nguyen","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R60-3-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/10445460152595586","article-title":"A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.","volume":"11","author":"Posey","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R61-3-20210129","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10803-006-0123-0","article-title":"Comorbid psychiatric disorders in children with autism: interview development and rates of disorders.","volume":"36","author":"Leyfer","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"R62-3-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02578400","article-title":"Stimulant drugs in the developmental disabilities revisited.","volume":"4","author":"Aman","year":"1996","journal-title":"J Dev Phys Disabil"},{"key":"R63-3-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF01538042","article-title":"A controlled crossover study of triiodothyronine in autistic children.","volume":"8","author":"Campbell","year":"1978","journal-title":"J Autism Child Schizophr"},{"key":"R64-3-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/104454604773840481","article-title":"A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R65-3-20210129","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004583-198803000-00020","article-title":"Methylphenidate treatment of hyperactive autistic children.","volume":"27","author":"Birmaher","year":"1988","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R66-3-20210129","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/ajp.138.3.388","article-title":"Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity.","volume":"138","author":"Geller","year":"1981","journal-title":"Am J Psychiatry"},{"key":"R67-3-20210129","first-page":"605","article-title":"The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels.","volume":"31","author":"Hoshino","year":"1977","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"R68-3-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004583-198803000-00019","article-title":"Randomized trial of methylphenidate for an autistic child.","volume":"27","author":"Strayhorn","year":"1988","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R69-3-20210129","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1176\/ajp.138.11.1517c","article-title":"Stimulant medication in certain childhood disorders.","volume":"138","author":"Vitriol","year":"1981","journal-title":"Am J Psychiatry"},{"key":"R70-3-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"R71-3-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder.","volume":"25","author":"Quintana","year":"1995","journal-title":"J Autism Dev Disord"},{"key":"R72-3-20210129","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R73-3-20210129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00004583-200102000-00012","article-title":"Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.","volume":"40","author":"Greenhill","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R74-3-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/cap.2008.0137","article-title":"Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficithyperactivity disorder symptoms in preschoolers with developmental disorders.","volume":"19","author":"Ghuman","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R75-3-20210129","first-page":"34","article-title":"Is schizophrenia on the autism spectrum Brain R","volume":"1380","author":"King","year":"2011","journal-title":"es"},{"key":"R76-3-20210129","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficithyperactivity disorder.","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"R77-3-20210129","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"R78-3-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficithyperactivity disorder: a placebo-controlled trial.","volume":"48","author":"Sallee","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R79-3-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/000992280003900102","article-title":"A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.","volume":"39","author":"Connor","year":"2000","journal-title":"Clin Pediatr (Phila)"},{"key":"R80-3-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaac.2010.11.005","article-title":"Clonidine extended-release tablets for pediatric patients with attention-deficithyperactivity disorder.","volume":"50","author":"Jain","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R81-3-20210129","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1542\/peds.2010-1260","article-title":"Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.","volume":"127","author":"Kollins","year":"2011","journal-title":"Pediatrics"},{"key":"R82-3-20210129","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders.","volume":"30","author":"Ming","year":"2008","journal-title":"Brain Dev"},{"key":"R83-3-20210129","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"R84-3-20210129","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder.","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"R85-3-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R86-3-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders.","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R87-3-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism andor intellectual disabilities.","volume":"29","author":"Handen","year":"2008","journal-title":"J Dev Behav Pediatr"},{"key":"R88-3-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/cap.2005.15.325","article-title":"Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.","volume":"15","author":"Jou","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R89-3-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficithyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R90-3-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficithyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R91-3-20210129","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1651-2227.2011.02263.x","article-title":"Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficithyperactivity disorder.","volume":"100","author":"Zeiner","year":"2011","journal-title":"Acta Paediatr"},{"key":"R92-3-20210129","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1087054710376907","article-title":"Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.","volume":"15","author":"Charnsil","year":"2011","journal-title":"J Atten Disord"},{"key":"R93-3-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"A randomized double-blind study of atomoxetine versus placebo for attention-deficithyperactivity disorder symptoms in children with autism spectrum disorder.","volume":"51","author":"Harfterkamp","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R94-3-20210129","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R95-3-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R96-3-20210129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems.","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"key":"R97-3-20210129","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"R98-3-20210129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R99-3-20210129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","article-title":"Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.","volume":"41","author":"Malone","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R100-3-20210129","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study.","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J Child Neurol"},{"key":"R101-3-20210129","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R102-3-20210129","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.","volume":"48","author":"Aman","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R103-3-20210129","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism.","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R104-3-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"R105-3-20210129","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","article-title":"Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.","volume":"161","author":"Martin","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R106-3-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R107-3-20210129","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R108-3-20210129","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"R109-3-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.","volume":"20","author":"Aman","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R110-3-20210129","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.09m05933","article-title":"Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.","volume":"72","author":"Marcus","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R111-3-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/cap.2011.0129","article-title":"The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.","volume":"22","author":"Ho","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R112-3-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.","volume":"40","author":"Malone","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R113-3-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","article-title":"Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.","volume":"19","author":"Potenza","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R114-3-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000141508","article-title":"Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.","volume":"17","author":"Fido","year":"2008","journal-title":"Med Princ Pract"},{"key":"R115-3-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","article-title":"Open-label study of olanzapine in children with pervasive developmental disorder.","volume":"22","author":"Kemner","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R116-3-20210129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhoodadolescent pervasive developmental disorder.","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R117-3-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/1044546041649129","article-title":"Quetiapine in nine youths with autistic disorder.","volume":"14","author":"Findling","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R118-3-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","article-title":"Open-label quetiapine in the treatment of children and adolescents with autistic disorder.","volume":"9","author":"Martin","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R119-3-20210129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNF.0b013e31823349ac","article-title":"Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.","volume":"34","author":"Golubchik","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"R120-3-20210129","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.","volume":"65","author":"Corson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R121-3-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders.","volume":"35","author":"Hardan","year":"2005","journal-title":"J Autism Dev Disord"},{"key":"R122-3-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/cap.2006.00136","article-title":"Ziprasidone for maladaptive behavior and attention-deficithyperactivity disorder symptoms in autistic disorder.","volume":"17","author":"Duggal","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R123-3-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1614.2003.01279.x","article-title":"Improvement in behaviour and attention in an autistic patient treated with ziprasidone.","volume":"37","author":"Goforth","year":"2003","journal-title":"Aust N Z J Psychiatry"},{"key":"R124-3-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","article-title":"Ziprasidone in adolescents with autism: an open-label pilot study.","volume":"17","author":"Malone","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R125-3-20210129","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism.","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R126-3-20210129","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4088\/JCP.v65n0119","article-title":"The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.","volume":"65","author":"Cohen","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R128-3-20210129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0028-1102913","article-title":"Paliperidone in an adult patient with Asperger syndrome: case report.","volume":"42","author":"Roser","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"R129-3-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/cap.2009.0019","article-title":"Paliperidone for irritability in autistic disorder.","volume":"20","author":"Stigler","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R130-3-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-012-2711-3","article-title":"Paliperidone for irritability in adolescents and young adults with autistic disorder.","volume":"223","author":"Stigler","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R131-3-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","article-title":"Clozapine in the treatment of aggression in an adolescent with autistic disorder.","volume":"62","author":"Chen","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R132-3-20210129","first-page":"340","article-title":"Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour.","volume":"26","author":"Gobbi","year":"2001","journal-title":"J Psychiatry Neurosci"},{"key":"R133-3-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2009.0057","article-title":"Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder.","volume":"20","author":"Lambrey","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R134-3-20210129","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/ajp.153.5.738a","article-title":"Clinical effects of clozapine on autistic disorder.","volume":"153","author":"Zuddas","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R135-3-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.","volume":"26","author":"De Hert","year":"2012","journal-title":"CNS Drugs"},{"key":"R136-3-20210129","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.jcp.0000227703.72117.bc","article-title":"Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.","volume":"26","author":"Anagnostou","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R137-3-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01376517-199708000-00005","article-title":"Valproic acid treatment of epilepsy in autistic twins.","volume":"29","author":"Childs","year":"1997","journal-title":"J Neurosci Nurs"},{"key":"R138-3-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archpedi.1994.02170020106021","article-title":"Autism: electroencephalogram abnormalities and clinical improvement with valproic acid.","volume":"148","author":"Plioplys","year":"1994","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R139-3-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders.","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R140-3-20210129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R141-3-20210129","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R142-3-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.","volume":"9","author":"Hollander","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"R143-3-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"key":"R144-3-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R145-3-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","article-title":"Levetiracetam in autistic children: an open-label study.","volume":"23","author":"Rugino","year":"2002","journal-title":"J Dev Behav Pediatr"},{"key":"R146-3-20210129","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1176\/ajp.2007.164.5.832","article-title":"Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors.","volume":"164","author":"Kapetanovic","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R147-3-20210129","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10803-012-1661-2","article-title":"Brief report: retrospective case series of oxcarbazepine for irritabilityagitation symptoms in autism spectrum disorder.","volume":"43","author":"Douglas","year":"2013","journal-title":"J Autism Dev Disord"},{"key":"R148-3-20210129","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/cap.2004.14.426","article-title":"A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.","volume":"14","author":"Hardan","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R149-3-20210129","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.braindev.2006.05.004","article-title":"Topiramate in children with autistic spectrum disorders.","volume":"28","author":"Mazzone","year":"2006","journal-title":"Brain Dev"},{"key":"R150-3-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.braindev.2004.06.006","article-title":"Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders.","volume":"27","author":"Canitano","year":"2005","journal-title":"Brain Dev"},{"key":"R151-3-20210129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbr.2012.08.011","article-title":"Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders.","volume":"251","author":"Lukas","year":"2013","journal-title":"Behav Brain Res"},{"key":"R152-3-20210129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0006-3223(97)00439-3","article-title":"Plasma oxytocin levels in autistic children.","volume":"43","author":"Modahl","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R153-3-20210129","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/npp.2011.333","article-title":"Effects of a common variant in the CD38 gene on social processing in an oxytocin challenge study: possible links to autism.","volume":"37","author":"Sauer","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R154-3-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.biopsych.2006.07.015","article-title":"Oxytocin improves mind-reading in humans.","volume":"61","author":"Domes","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R155-3-20210129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2040-2392-3-16","article-title":"Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.","volume":"3","author":"Anagnostou","year":"2012","journal-title":"Mol Autism"},{"key":"R156-3-20210129","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol Psychiatry"},{"key":"R157-3-20210129","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2006.05.030","article-title":"Oxytocin increases retention of social cognition in autism.","volume":"61","author":"Hollander","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R158-3-20210129","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-244X-12-110","article-title":"Long-term oxytocin administration improves social behaviors in a girl with autistic disorder.","volume":"12","author":"Kosaka","year":"2012","journal-title":"BMC Psychiatry"},{"key":"R159-3-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.npp.1300021","article-title":"Oxytocin infusion reduces repetitive behaviors in adults with autistic and Aspergers disorders.","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R161-3-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2009.07.016","article-title":"Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.","volume":"58","author":"Ring","year":"2010","journal-title":"Neuropharmacology"},{"key":"R162-3-20210129","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.pbb.2011.02.003","article-title":"Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.","volume":"100","author":"Carlson","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"R163-3-20210129","doi-asserted-by":"crossref","first-page":"e36981","DOI":"10.1371\/journal.pone.0036981","article-title":"The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome.","volume":"7","author":"Wei","year":"2012","journal-title":"PLoS One"},{"key":"R164-3-20210129","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0883073807302611","article-title":"Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.","volume":"22","author":"Chez","year":"2007","journal-title":"J Child Neurol"},{"key":"R165-3-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders.","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R166-3-20210129","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4088\/JCP.v67n0619h","article-title":"Memantine for disruptive behavior in autistic disorder.","volume":"67","author":"Erickson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R167-3-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R168-3-20210129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.brainres.2010.10.108","article-title":"Open-label riluzole in fragile X syndrome.","volume":"1380","author":"Erickson","year":"2011","journal-title":"Brain Res"},{"key":"R169-3-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/cap.2007.0021","article-title":"An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.","volume":"17","author":"Grant","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R170-3-20210129","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2006.08.037","article-title":"Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.","volume":"61","author":"Sanacora","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R171-3-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1176\/appi.ajp.161.1.171","article-title":"An open-label trial of riluzole in patients with treatment-resistant major depression.","volume":"161","author":"Zarate","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R172-3-20210129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biopsych.2004.11.023","article-title":"An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.","volume":"57","author":"Zarate","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R173-3-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cap.2009.0087","article-title":"Increase in valproic acid levels during riluzole treatment in an adolescent with autism.","volume":"20","author":"Veenstra-VanderWeele","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R174-3-20210129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/cap.2010.0154","article-title":"Riluzole in autistic disorder.","volume":"21","author":"Wink","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R175-3-20210129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/cap.2010.0009","article-title":"Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.","volume":"20","author":"Grant","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R176-3-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature11208","article-title":"Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function.","volume":"486","author":"Won","year":"2012","journal-title":"Nature"},{"key":"R177-3-20210129","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of D-cycloserine in subjects with autistic disorder.","volume":"161","author":"Posey","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R178-3-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","article-title":"A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.","volume":"179","author":"Goff","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R179-3-20210129","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.neubiorev.2011.06.006","article-title":"A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism.","volume":"35","author":"Moskal","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"R180-3-20210129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophreniaa double-blind, randomized, placebo-controlled trial.","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R181-3-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","article-title":"N-acetyl cysteine for depressive symptoms in bipolar disordera double-blind randomized placebo-controlled trial.","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R182-3-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jad.2011.06.005","article-title":"The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.","volume":"135","author":"Berk","year":"2011","journal-title":"J Affect Disord"},{"key":"R183-3-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.","volume":"62","author":"Grant","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R184-3-20210129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R185-3-20210129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1516-44462011000400011","article-title":"N-acetylcysteine for major depressive episodes in bipolar disorder.","volume":"33","author":"Magalhaes","year":"2011","journal-title":"Rev Bras Psiquiatr"},{"key":"R186-3-20210129","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"R187-3-20210129","doi-asserted-by":"crossref","first-page":"152ra27","DOI":"10.1126\/scitranslmed.3004214","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.","volume":"4","author":"Berry-Kravis","year":"2012","journal-title":"Sci Transl Med"},{"key":"R190-3-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijdevneu.2004.05.012","article-title":"Making and breaking serotonin neurons and autism.","volume":"23","author":"Scott","year":"2005","journal-title":"Int J Dev Neurosci"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HRP.0000000000000030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T22:20:00Z","timestamp":1716589200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-201403000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":181,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/hrp.0000000000000030","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}